NF2 mutations activate the Hippo/YAP signaling pathway, which has been shown to upregulate PD-L1 expression in tumors like melanoma and lung cancer [68,69], potentially making NF2-mutant tumors more immunoevasive. This evidence concerns the gene NF2 and lung cancer.